Land: Australia
Språk: engelsk
Kilde: Department of Health (Therapeutic Goods Administration)
timolol maleate, Quantity: 6.83 mg/mL (Equivalent: timolol, Qty 5 mg/mL); dorzolamide hydrochloride, Quantity: 22.26 mg/mL (Equivalent: dorzolamide, Qty 20 mg/mL)
Mundipharma Pty Ltd
Eye Drops, solution
Excipient Ingredients: benzalkonium chloride; mannitol; sodium hydroxide; water for injections; hyetellose; sodium citrate dihydrate
Ophthalmic
5mL
(S4) Prescription Only Medicine
Cosopt is indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma when concominant therapy is appropriate.
Visual Identification: Clear, colourless to nearly colourless, slightly viscous solution.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Restricted flow insert
Licence status A
1999-09-02
COSOPT ® 1 COSOPT ® Dorzolamide hydrochloride/Timolol maleate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about COSOPT. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using COSOPT against the benefits they expect it will have for you. If you have any concerns about using this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What COSOPT is used for COSOPT is used to lower raised pressure in the eye and to treat glaucoma. Glaucoma is a condition in which the pressure of fluid in the eye may be high. However, some people with glaucoma may have normal eye pressure. Also, some people with raised eye pressure may not have glaucoma. Glaucoma is usually caused by a build-up of the fluid which flows through the eye. This build up occurs because the fluid drains out of your eye more slowly than it is being pumped in. Since new fluid continues to enter the eye, joining the fluid already there, the pressure continues to rise. This raised pressure may damage the back of the eye resulting in gradual loss of sight. Damage can progress so slowly that the person is not aware of this gradual loss of sight. Sometimes even normal eye pressure is associated with damage to the back of the eye. There are usually no symptoms of glaucoma. The only way of knowing that you have glaucoma is to have your eye pressure, optic nerve and visual field checked by an eye specialist or optometrist. If glaucoma is not treated it can lead to serious problems. You may have no symptoms but eventually glaucoma can lead to total blindness. In fact, untreated glaucoma is one of the most common causes of blindness. Although COSOPT helps control your glaucoma it does not cure it. For more information about glaucoma, contact Glaucoma Australia Inc., PO Box 420, Crows Nest 1585, telephone 1800 500 read_full_document
COSOPT® EYE DROPS Page 1 of 14 AUSTRALIAN PRODUCT INFORMATION – COSOPT [DORZOLAMIDE (AS HYROCHLORIDE) AND TIMOLOL (AS MALEATE)] EYE DROPS 1 NAME OF THE MEDICINE Dorzolamide hydrochloride and timolol maleate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION COSOPT is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution. Each millilitre of COSOPT contains 20.00 mg (2.0% w/v) dorzolamide (22.26 mg of dorzolamide hydrochloride) and 5.00 mg (0.5% w/v) timolol (6.83 mg of timolol maleate) as the active ingredients. List of excipient(s) with known effect: benzalkonium chloride. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Eye drops, solution. Clear, colourless to nearly colourless, slightly viscous solution. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS COSOPT is indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate. 4.2 D OSE AND METHOD OF ADMINISTRATION The dose is one drop of COSOPT in the affected eye(s) two times daily. When substituting COSOPT for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start COSOPT on the next day. If another topical ophthalmic agent is being used, COSOPT and the other agent should be administered at least ten minutes apart. Efficacy in paediatric patients has not been established. Safety in paediatric patients below the age of 2 years has not been established (For information regarding safety in paediatric patients ≥2 and <6 years of age, see Section 4.4 Special Warnings and Precautions for Use/Paediatric Use). COSOPT® EYE DROPS Page 2 of 14 4.3 C ONTRAINDICATIONS COSOPT is contraindicated in patients with: reactive airway disease, bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia, sino-atrial block, second or third degree atrioventricular block, overt cardiac failu read_full_document